NCT01045421 - Alisertib in Adults With Nonhematological Malignancies, Followed by Alisertib in Lung, Breast, Head and Neck or Gastroesophageal Malignancies | Biotech Hunter

Enrollment

273

Participants

Timeline

Start Date

February 28, 2010

Primary Completion Date

May 31, 2013

Study Completion Date

April 30, 2014

Conditions

Advanced Nonhematological MalignanciesNon-Small Cell Lung CancerSmall Cell Lung CancerMetastatic Breast CancerHead and Neck Squamous Cell CarcinomaGastroesophageal Adenocarcinoma

Interventions

DRUG

MLN8237 (Alisertib)

"Phase 1:~MLN8237 will be administered orally twice a day on a 7-day dosing schedule~Phase 2:~MLN8237 will be administered orally at the maximum tolerated dose determined in Phase 1 for 7-days followed by a minimum 14-day rest period."

Trial Locations (2)

Unknown

Houston

Salt Lake City